Climb Bio, Inc.
CLYM- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001768446
In the last 90 days, Climb Bio, Inc. insiders filed 0 open-market purchases and 1 sale; 108 institutions reported holding it in 13F filings for Q2 2026, worth $734.3M in total; no superinvestor holds it.
Q3 2022 vs. Q2 2022
How the institutions holding Climb Bio, Inc. changed between Q2 2022 and Q3 2022.
All holders in Q3 2022All holders in Q2 2022
| Measure | Q2 2022 | Q3 2022 | Change |
|---|---|---|---|
| Holders | 29 | 22 | −7 |
| Shares | 15.1M | 14.8M | −320.7K (−2.1%) |
| Value | $45.7M | $47.8M | +$2.13M (+4.7%) |
New holders (2)
Institutions that held Climb Bio, Inc. at the end of Q3 2022 but not at the end of Q2 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Driehaus Capital Management LLC | 348,571 | $1.13M | 0.02% |
| BNP Paribas Arbitrage, SA | 158 | $510 | 0.00% |
Sold out (9)
Institutions that held Climb Bio, Inc. at the end of Q2 2022 and filed for Q3 2022 without it.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| Goldman Sachs Group Inc | 162,792 | $492.0K |
| Parkwood LLC | 67,202 | $203.0K |
| Ergoteles LLC | 26,364 | $80.0K |
| UBS Group AG | 2,282 | $7.00K |
| Legal & General Group Plc | 560 | $2.00K |
| FMR LLC | 9 | $0 |
| New York State Common Retirement Fund | 59 | $0 |
| Credit Suisse AG | 3 | $0 |
| Citigroup Inc | 53 | $0 |